ORDERS $150+ QUALIFY FOR FREE SHIPPING

Menu

Retatrutide

Retatrutide is a synthetic tri-agonist peptide engineered to interact with GLP-1, GIP, and glucagon receptor signaling pathways. Through this tri-agonist mechanism, it is utilized in research settings to study metabolic signaling processes, receptor signaling pathways, and peptide-mediated cellular communication. Supplied by Peptico for research-use only.

- +

All Orders Ship within
24 Business Hours

Free Shipment Protection

Priority Shipment Options Available at Checkout

Format
Lyophilized powder
Approved Exclusively For
Laboratory and Analytical Research
Handling
Utilize appropriate sterile technique and controlled environments during preparation.
Short-Term Storage - Lyophilized Powder Form Only
  • For maximum potency, lyophilized materials may generally be stored between 2°C and 8°C (36°F to 46°F) for up to 4 weeks when maintained in their original, sealed lyophilized form.
  • Maintain a cool and dry environment.
  • Protect from moisture and light.
  • Minimize exposure to humidity and temperature fluctuations.
Long-Term Storage - Lyophilized Powder Form Only
  • For maximum potency and long-term preservation, lyophilized materials may generally be stored between -20°C and -80°C (-4°F to -112°F) for up to 1 year when preserved in their original, sealed lyophilized form.
  • Maintain a cool and dry environment.
  • Protect from moisture and light.
  • Minimize exposure to humidity and temperature fluctuations.

Important Note:

Storage guidelines apply only to lyophilized material in its original, sealed, and untampered vial.

COA History

All shipped products include a unique batch number printed on the vial label. This batch number corresponds to a third-party Certificate of Analysis tested by an ISO/IEC 17025 accredited laboratory.


The COA attached at the top of this page, along with the COA marked “Current” below, represents the active production batch currently being shipped. This same batch number will appear on the label of your vial.


For previous purchases, please refer to COAs marked “Historical” and match the batch number on your vial to the batch number listed on the corresponding COA.


For a complete record of testing documentation across all products and batches, please visit our COA Vault, which includes both current and historical COAs.

Loading COA history...

Frequently Researched Together:

Molecular Profile

What is Retatrutide?

No PubChem molecular profile was found for this product.

Research

Sources & References

API results related to Retatrutide.

PubMed Scientific paper

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Annals of internal medicine

Damen JAA, Idema DL, Vernooij RWM et al. • 2026

Publication date: 2026 Jun 16

View source
PubMed Scientific paper

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Lancet (London, England)

Bajaj HS, Welch M, Shah P et al. • 2026

Publication date: 2026 Jun 13

View source
PubMed Scientific paper

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.

Diabetes, metabolic syndrome and obesity : targets and therapy

Abid M, Sheikh KS, Ahmad MS et al. • 2026

Publication date: 2026

View source
PubMed Scientific paper

A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.

Organic letters

Mao CY, Pang ZJ, Qiao GY et al. • 2026

Publication date: 2026 Jun 12

View source
PubMed Scientific paper

Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.

BMJ (Clinical research ed.)

Lang K • 2026

Publication date: 2026 Jun 9

View source
PubMed Scientific paper

Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.

Current obesity reports

Xie J, Yang Y, Chen W et al. • 2026

Publication date: 2026 Jun 6

View source

⚠️ IMPORTANT RESEARCH NOTICE

This product is NOT for human consumption.
Supplied strictly for laboratory and analytical research use only, it is not intended to diagnose, treat, cure, or prevent any disease, and must not be used for clinical, veterinary, or therapeutic applications.
All information provided, including referenced research and data, is for educational and scientific context only and should NOT be interpreted as medical guidance.
By purchasing, you confirm that you are a qualified individual or entity operating in accordance with applicable local, state, and federal regulations. All responsibility for handling, use, and compliance rests solely with the purchaser.

Scroll to Top